Information on Q1 2017 Financial Results Q1 2017 Change Change at CER IFRS net sales reported 8,648m +11.1 % +8.6 % IFRS net income reported 5,701m +424.5 % IFRS EPS reported 4.52 +438.1 % Business net income (1) 1,795m

Information on Q1 2017 Financial Results

First-quarter 2017 accounts reflect the acquisition of the former Boehringer Ingelheim Consumer Healthcare (CHC) business

and the disposal of the Animal Health business (completed on January 1, 2017(2)). In accordance with IFRS 5 (Non-Current Assets Held for Sale and

Discontinued Operations), Animal Health results in 2016 and gain on disposal in 2017 are reported separately. The first quarter 2017 income statement also reflects the consolidation of European operations related to Sanofi vaccine portfolio,

following the termination of the Sanofi Pasteur MSD joint venture (SPMSD JV) with Merck at the end of December 2016.

2017 first-quarter Sanofi sales

Unless otherwise indicated, all percentage changes in sales in this press release are stated at

In the first quarter of 2017, Company sales were 8,648 million, up 11.1% on a

reported basis. Exchange rate movements had a favorable effect of 2.5 percentage points reflecting mainly the positive evolution of the U.S. dollar, Brazilian Real and Japanese Yen which more than offset the negative impact from the Egyptian Pound,

Turkish Lira and British Pound. Company sales benefited from the acquisition of BI s CHC business and full consolidation of Sanofi s European vaccines operations leading to an increase of 8.6% at CER.

Global Business Units

The table below presents sales by

Global Business Unit (GBU) and reflects the organization of Sanofi which became effective as of January 1, 2016. This structure drives deeper specialization, simplifies reporting and provides clear focus on growth drivers. Please note that in

Emerging Markets, Specialty Care and Diabetes and Cardiovascular sales are included in the General Medicines and Emerging Markets GBU.

The table below presents first quarter

2017 sales by global franchise, including Emerging Markets sales, to facilitate comparisons. Appendix 1 provides a reconciliation of sales by GBU and franchise.

First-quarter Pharmaceuticals sales increased 7.4% to 7,864 million.

Rare Disease franchise

In the first quarter, Rare Disease sales increased 7.6% to 712 million driven by the accrual of patients worldwide.

Rare Disease sales grew at double digits in the U.S. and Emerging Markets, up 12.2% and 11.1%, respectively.

In the first quarter, Gaucher

(Cerezyme and Cerdelga ) sales decreased 1.0% to 207 million, due to lower Cerezyme sales in Emerging Markets (down 10.7% to 50 million) mostly driven by ordering patterns in Latin America. Cerdelga sales increased

30.4% to 31 million of which 25 million were generated in the U.S. (up 26.3%).

First-quarter Fabrazyme sales were up 15.4% to 177 million, reflecting a continued accrual of new Fabry patients.

sales increased 12.7% to 190 million in the first quarter, mainly due to new patient accruals and increased worldwide diagnosis of Pompe disease.

Multiple Sclerosis franchise

First-quarter Multiple Sclerosis (MS) sales increased 32.4% to 496 million, reflecting strong Aubagio and Lemtrada performance in the U.S. and Europe.

In the first quarter, Aubagio sales

increased 29.7% to 371 million driven by the U.S. (up 33.0% to 259 million) and Europe (up 23.0% to 91 million). In the U.S., Aubagio has achieved market share of 9.0%

(source IMS TRX-Q1 2017) and is now the most switched to disease modifying therapy in the U.S. (source IMS NPA Market Dynamics).

First-quarter Lemtrada sales increased 40.9% to 125 million, including

67 million in the U.S. (up 39.1%) and 45 million in Europe (up 31.4%).

First-quarter Oncology sales increased 12.8% to 412 million driven mainly by Jevtana and boosted by a U.S. government order for Leukine . Jevtana sales were up 5.6% to 97 million in the first quarter led by Europe (up 5.7% to 37 million) and Japan. In the first quarter, Thymoglobulin sales increased 7.7% to 72 million supported by the U.S. (up 8.1% to 41 million).

Eloxatin sales increased 7.1% to

45 million in the first quarter supported by China (Emerging Markets sales were up 27.6% to 37 million) which offset generic competition in Canada. First-quarter

Taxotere sales increased 2.2% (to 47 million) driven by Emerging Markets (up 23.3% to 37) which offset continued generic competition in Japan.

In the first quarter, Diabetes sales decreased 6.0% to 1,663 million, including lower Lantus sales in the U.S. First-quarter U.S. Diabetes sales were down 14.7% to 839 million. Sales in Emerging Markets increased 12.1% to 373 million. Sales in Europe were

326 million, a decrease of 3.0%.

In the first quarter, Sanofi glargine

(Lantus and Toujeo ) sales decreased 7.7% to 1,418 million. In the U.S., Sanofi glargine sales of 805 million

were down 15.5% and reflected the impact of the exclusion from various CVS commercial formularies. The U.S. Diabetes sales decline is expected to accelerate over the remainder of the year primarily due to the United Health formulary exclusion which

started April 1, 2017 as well as an incremental impact from the CVS formulary exclusion. In Europe, Sanofi glargine sales decreased 3.1% to 245 million due to biosimilar competition in several European markets.

Over the quarter, Lantus sales were 1,226 million down 14.1%. In the U.S., Lantus sales decreased 20.9% to 690 million mainly reflecting lower average net price and patients switching to Toujeo as well as the

aforementioned impact of formulary exclusions. In Europe, first-quarter Lantus sales were 199 million (down 14.8%) due to biosimilar competition and patients switching to Toujeo . In Emerging Markets, sales were up 9.6% to 253 million.

First-quarter Toujeo sales were 192 million (up 78.6%) of which 115 million (up 42.3%) were recorded in the U.S. and 46 million in Europe.

Amaryl sales were 89 million, up 5.7% in the first quarter, of which

73 million were generated in Emerging Markets (up 8.5%).

First-quarter Apidra

sales increased 14.1% to 98 million, reflecting double digit growth in the U.S. (up 12.0% to 29 million), Europe (up 12.9% to 35 million), and Emerging Markets (up 20.0% to 24 million).

Since January 2017, Soliqua 100/33 (insulin glargine 100 Units/mL & lixisenatide 33 mcg/mL injection; lixisenatide was in-licensed from Zealand Pharma) has been available in the U.S. Soliqua sales were 4 million in the first quarter.

Cardiovascular franchise

First-quarter Praluent sales (collaboration with Regeneron) were 34 million of which 24 million was in the U.S. and 8 million in Europe. This reflected significant payer utilization

management restrictions in the U.S. and limited market access in Europe.

In January 2017, the U.S. District Court for the District of Delaware issued an

injunction that required Sanofi and Regeneron to stop marketing, selling and manufacturing Praluent in the U.S. starting from February 21, 2017. However, on February 8, 2017, the

Court of Appeals for the Federal Circuit stayed (suspended) the permanent injunction for Praluent pending the companies appeal. As a result, Sanofi and Regeneron will continue

marketing, selling and manufacturing Praluent in the U.S. during the appeal process. The Court of Appeals is scheduled to hear oral arguments on June 6, 2017.

First-quarter Multaq sales were 98 million, up 10.5% reflecting 9.6% growth (to

83 million) in the U.S.

Established Rx Products

In the first quarter, Established Rx Products sales increased 0.6% to 2,640 million,

reflecting strong performance in Emerging Markets (up 8.2% to 1,006 million) which offset the impact of generic competition to Plavix in Japan. In the U.S., Established Rx Products

sales decreased 4.9% (to 365 million). In Europe, Established Rx Products sales decreased 2.1% to 907 million.

Lovenox sales increased 2.2% to 415 million in the first quarter, driven by strong performance in Emerging Markets (up 14.3% to 120

million), which offset lower sales in Europe (down 1.5% to 257 million).

In the first quarter, Plavix sales were down 1.8% to 380 million due to generic competition in Japan that started in June 2015 (sales in Japan were down 33.7%

to 64 million). In Emerging Markets, Plavix sales increased 10.8% to 262 million sustained by the performance in China.

Renvela /Renagel sales increased 2.1% to

246 million. In the U.S. where Sanofi expects generic competition before the end of 2017, first-quarter sales were up 3.1% to 207 million. In Europe, Renvela /Renagel sales were down 13.6% to 18 million due to generic competition.

Aprovel /Avapro sales

were up 13.0% (to 193 million) driven by product sales to our partner in Japan and sales in China.

CHC sales by geography and category are provided in Appendix 1.

In the first quarter, Consumer Healthcare (CHC) sales increased 42.7% to 1,341 million reflecting the

closing of the acquisition of Boehringer Ingelheim CHC business on January 1st, 2017 and the transfer of some Sanofi products to the new Chinese joint-venture between Sanofi and China Resources

In Europe, CHC sales were up 68.2% to 406 million.

In the U.S., first quarter CHC sales increased 18.7% to 348 million.

In Emerging Markets, first-quarter CHC sales increased 20.9% to 404 million.

In the rest of the world, CHC sales were up 151.5% to 183 million.

In the first quarter, Generics sales

decreased 2.0% to 468 million reflecting lower sales in Europe (down 3.4% to 198 million), and a 2.8% increase in Emerging Markets (to 200 million).

As announced in our 2020 strategic roadmap, Sanofi has carefully reviewed all options for our Generics business in Europe and made the definitive decision to

initiate a carve-out process expected to be completed by the end of 2018. Importantly, Sanofi confirms its commitment to Generics in other parts of the world with a greater focus on the Emerging Markets.

First quarter consolidated Vaccines sales were up 22.2% to 784 million and reflected the termination of the

Sanofi Pasteur MSD joint-venture in Europe from December 31, 2016. In the U.S., sales were up 13.5% to 287 million. In Emerging Markets, sales grew 11.5% to 316 million. In Europe, sales were up 110.4% to

100 million reflecting the termination of SPMSD JV..

In the first quarter, Polio/Pertussis/Hib vaccines sales increased 46.2% to

Influenza vaccines sales were up 85.0% to 38 million boosted by supply to Butantan in Brazil in the

First-quarter Adult Booster vaccines sales were 79 million, down 5.0%.

First quarter Dengvaxia sales were

17 million mainly reflecting the sales of the third dose for the public immunization program implemented in the Philippines at the beginning of 2016.